Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Gabrielson

Showing results (41-50 of 44) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 44 results.
Journal of the National Cancer Institute|April 6, 2000
Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumorsM Esteller, J M Silva, G Dominguez, et al.
British Journal of Cancer|February 20, 2008
Frequent epigenetic inactivation of Wnt antagonist genes in breast cancerH Suzuki, M Toyota, H Carraway, et al.
Nature Genetics|October 1, 1995
Frequency of homozygous deletion at p16/CDKN2 in primary human tumoursP Cairns, T J Polascik, Y Eby, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 9, 2018
Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC)T R Cottrell, E D Thompson, P M Forde, et al.
Pageof 5

Showing results (41-50 of 44) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 44 results.
Journal of the National Cancer Institute|April 6, 2000
Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumorsM Esteller, J M Silva, G Dominguez, et al.
British Journal of Cancer|February 20, 2008
Frequent epigenetic inactivation of Wnt antagonist genes in breast cancerH Suzuki, M Toyota, H Carraway, et al.
Nature Genetics|October 1, 1995
Frequency of homozygous deletion at p16/CDKN2 in primary human tumoursP Cairns, T J Polascik, Y Eby, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 9, 2018
Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC)T R Cottrell, E D Thompson, P M Forde, et al.
Pageof 5